A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Recruiting

I'm Interested

Trial ID: NCT05201781

Age - 18 Years-N/A Condition - Multiple Myeloma Gender - ALL Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Official Title

Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Stanford Investigator(s)

Surbhi Sidana, MD
Surbhi Sidana, MD

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility

Inclusion Criteria:

* Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
* Participants who have provided informed consent for this study

View More
View Less

Intervention(s):

drug: Cilta-cel

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kelly Chyan
650-625-8130

New Trial Alerts

©2025 Stanford Medicine